Special Issues
Table of Content

Immunotherapy for Breast Cancer

Submission Deadline: 31 December 2022 (closed)

Guest Editors

Dr. Shaojie Jiang
School of Medical Imaging, Hangzhou Medical College, Hangzhou 310053, Zhejiang, China.
jsj1983@hmc.edu.cn

Summary

Nowadays, immunotherapy has profoundly changed the treatment mode in various cancers, including breast cancer. More clinical trials are ongoing since the first approval of atezolizumab by the FDA for the treatment of triple-negative breast cancer (TNBC) in 2019. These ongoing studies are evaluating combination strategies pairing immune checkpoint blockades (ICBs) with additional chemotherapeutic agents, small targeted molecules, monoclonal antibodies, and local ablative therapies to enhance response in both early-stage and metastatic disease. However, reliable predictive biomarkers of response to ICBs have not been established.

 

This topic aims to advance knowledge related to molecular features, immune cell profiles, regulatory mechanisms, and monitoring and assessment in breast cancer immunotherapy. We welcome authors to submit original research, review, and perspective articles focusing on, but not limited to, new findings in the following areas:

 

• Biomarkers (including genes, proteins, metabolites, etc.) that can be used to predict or improve response to ICBs in breast cancer immunotherapy.

• Alterations of immune cell profiles in breast cancer immunotherapy and their meanings to the immunotherapy process.

• Immune-related signaling pathways alterations of tumor-resident immunocytes and tumor cells in breast cancer immunotherapy and their meanings to the immunotherapy process.

• The mechanisms of progressive/hyper-progressive diseases in breast cancer immunotherapy.

• Communications among tumor-resident immunocytes, tumor cells, and stromal cells (or other types of cells) in tumor niche in breast cancer immunotherapy.

• The new strategies of treatment, monitoring, assessment, and management in breast cancer immunotherapy, such as artificial intelligence, mathematical model, and imaging evaluation, nanotechnology, proteolysis targeting chimeras (PROTAC) technology, and oncolytic virus therapy.


Keywords

Breast Cancer, Immunotherapy, Immune Checkpoint Blockades, Biomarkers, Immune Cell Profiles, Immune-Related Signaling Pathways, Progressive/Hyper-Progressive Diseases

Published Papers


  • Open Access

    REVIEW

    Mechanisms and applications of antitumor immunotherapy of responsive drug-loaded nanoparticles in breast cancer

    LETIAN JIN, HETING CHEN, QI RUAN, RUI LIU, YIFENG FAN, XIUFANG XU, DAJIANG WANG, JIAHUI LU
    BIOCELL, Vol.47, No.7, pp. 1483-1498, 2023, DOI:10.32604/biocell.2023.028457
    (This article belongs to the Special Issue: Immunotherapy for Breast Cancer)
    Abstract During the chemotherapy of tumors, the cytotoxic effect of drugs is vital to kill tumor cells, and the delivery of a chemotherapeutic agent is of great importance for optimal therapeutic effects. The high in vivo clearance rate and low delivery efficiency of conventional chemotherapeutic agents affect the therapeutic effect. In recent years, the responsive drug delivery nanosystem has received increasing concern owing to its excellent biocompatibility, stable delivery performance, and controlled drug release strategies. To lucidly explain the cytocidal and immunotherapeutic effects of such responsive nanosystems in breast cancer, this review discusses the various stimuli and More >

  • Open Access

    REVIEW

    The progress of combination therapy with immune checkpoint inhibitors in breast cancer

    KAIMIN FAN, JUNWEI WENG
    BIOCELL, Vol.47, No.6, pp. 1199-1211, 2023, DOI:10.32604/biocell.2023.028516
    (This article belongs to the Special Issue: Immunotherapy for Breast Cancer)
    Abstract Immunotherapy targets the dysfunctional immune system to induce cancer cell killing by CD8-positive T cells. Immune checkpoint inhibitors (ICIs), specifically anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA4 antibodies, have revolutionized the management of many malignancies due to their significant role in generating a durable clinical response. However, clinical data suggest that response rates to ICI monotherapy are low due to the immunologically silent characteristics of breast cancer (BC). Chemotherapy, surgery, radiotherapy, and targeted therapy were recently reported to alter the tumor microenvironment and enhance the ICI response. Some clinical studies supported that ICIs, in combination with More >

Share Link